Susquehanna International Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-12,200
Closed -$130K 11247
2019
Q4
$130K Sell
12,200
-14,000
-53% -$139K ﹤0.01% 9020
2019
Q3
$273K Sell
26,200
-18,400
-41% -$241K ﹤0.01% 8505
2019
Q2
$683K Buy
44,600
+18,200
+69% +$263K ﹤0.01% 6569
2019
Q1
$339K Buy
+26,400
New +$298K ﹤0.01% 7007
2018
Q4
Sell
-14,200
Closed -$236K 10436
2018
Q3
$236K Sell
14,200
-1,400
-9% -$22.4K ﹤0.01% 7935
2018
Q2
$250K Sell
15,600
-2,900
-16% -$51.8K ﹤0.01% 8189
2018
Q1
$283K Sell
18,500
-7,100
-28% -$111K ﹤0.01% 7725
2017
Q4
$399K Buy
25,600
+9,200
+56% +$123K ﹤0.01% 7063
2017
Q3
$182K Sell
16,400
-48,300
-75% -$454K ﹤0.01% 8084
2017
Q2
$595K Buy
64,700
+1,500
+2% +$12.5K ﹤0.01% 6315
2017
Q1
$540K Buy
+63,200
New +$576K ﹤0.01% 6341

Susquehanna International Group's STML Position: Q2 2020 in Review

Susquehanna International Group sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 59,168 shares — an estimated $286K sold.

Susquehanna International Group first reported a position in STML in Q4 2013 and held it in 19 quarters. The position peaked at $1.85M in Q4 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Susquehanna International Group reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Susquehanna International Group sold 59,168 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $286K.
  • Susquehanna International Group first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 19 quarters.
  • Susquehanna International Group's Stemline Therapeutics, Inc. position peaked at $1.85M in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Susquehanna International Group's 13F filing for Q2 2020, filed 14 Aug 2020.